cr-8

(R)-CR8 trihydrochloride (CR8, (R)-Isomer trihydrochloride) is a CDK1/2/5/7/9 inhibitor that acts as a molecular glue degrader with neuroprotective activity and induces apoptosis.

(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.

(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.

OICR-8268-acrylic acid-amino-PEG9-amine is an E3 Ligase Ligand-linker conjugate. This compound is utilized for the synthesis of OICR41114.

OICR-8268-acrylic acid is a ligand for E3 ubiquitin ligase. This compound can be linked to a target protein ligand via a linker to form OICR41114, which is applicable in cancer research.

OICR-8268 is a reversible ligand for the DCAF1 WDR domain, exhibiting a Kd of 38 nM, and facilitates the development of DCAF1-based PROTACs [1].

CR-8020 is a human-derived IgG1 antibody that targets the influenza A virus H3N2. It binds to the hemagglutinin (HA) of H3N2 strains, with an IC50 of 3.36 nM for A/Brisbane/10/2007 and 0.06 nM for A/Wyoming/3/2003. For isotype control, refer to HumanIgG1kappa, Isotype Control.

AZ084 is a potent, selective, allosteric, and orally active CCR8 antagonist (Ki: 0.9 nM) with potential to treat asthma.

GPR35 agonist 1 is a highly effective and specific GPR35/CXCR8 agonist (EC50: 5.8 nM).

LMD-009 is a non-peptide, selective CCR8 agonist that mediates chemotaxis, inositol phosphate accumulation, and calcium release, with an EC50 of 11–87 nM.

ML 145 is a selective and potent antagonist of human GPR35, with no significant activity against GPR35 in any of its immediate rodent homologs.ML 145 has potential anti-inflammatory activity for the study of immunoinflammation.ML 145 is a novel non-steroidal anti-inflammatory agent for the study of rheumatoid arthritis.

ML604086 suppresses CCL1 mediated chemotaxis and enhances intracellular Ca2 concentrations. ML604086 is a selective inhibitor of CCR8. It also inhibiting CCL1 binding to CCR8 on circulating T-cells.

CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.

pCR8 is a prodrug of CR8. It exhibits amphiphilic properties, enabling self-assembly into nanoparticles. Under high concentrations of H2O2 in the tumor microenvironment, pCR8 releases CR8. CR8 functions as a molecular glue degrader, effectively breaking down cell cycle-related proteins and possessing anti-tumor activity. pCR8 is applicable in research on cancers such as breast cancer.

R243 is CCR8 signaling and chemotaxis inhibitor.

ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8 μM, in human; 2.6 μM, in mouse). Displays no activity at CCR4/5 and CXCR3/4 and shows higher 28-fold selectivity over 26 other GPCRs (less selective at α2A and 5-HT receptors). Induces chemotaxis and inhibits Env-mediated (HIV) cell-cell fusion.

Difelikefalin (CR-845; FE-202845) is a peripherally restricted, selective kappa opioid receptor (KOR) agonist with anti-inflammatory properties, demonstrating potential for modulating pruritus in chronic kidney disease.

CCR8 antagonist 2 is a potent inhibitor of CCR8 (C-C Motif chemokine receptor 8), predominantly expressed on Treg and Th2 cells, and not on Th1 cells. CCR8 antagonist 2 can be used for the treatment of CCR8-mediated diseases (e.g., cancer and/or neuropathic pain).

(2S,4aR,4bS,6aS,7aS,8aS,8bS,8cR,8dR,9aR,9bR)-2,9b-Dihydroxy-4a,6a-dimethylhexadecahydro-1H-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-7(7aH)-one is a useful organic compound for research related to life sciences. The catalog number is T67508 and the CAS number is 82543-16-6.

Difelikefalin TFA is a κ-opioid receptor (KOR) agonist. It activates KOR in HEK293 cells expressing the human receptor (EC50 = 0.16 nM in a transactivation assay) and inhibits forskolin-induced cAMP production in R1.G1 mouse thyoma cells (EC50 = 0.048 nM). Difelikefalin TFA is selective for KOR over the μ-opioid receptor (MOR; EC50 = >1 µM in a transactivation assay). It reduces acetic acid-induced writhing, as well as scratching behavior induced by the KOR antagonist GNTI, in mice (ED50s = 0.07 and 0.05 mg/kg, respectively).

Difelikefalin HCl is a κ-opioid receptor (KOR) agonist. It activates KOR in HEK293 cells expressing the human receptor (EC50 = 0.16 nM in a transactivation assay) and inhibits forskolin-induced cAMP production in R1.G1 mouse thyoma cells (EC50 = 0.048 nM). Difelikefalin HCl is selective for KOR over the μ-opioid receptor (MOR; EC50 = >1 µM in a transactivation assay). It reduces acetic acid-induced writhing, as well as scratching behavior induced by the KOR antagonist GNTI, in mice (ED50s = 0.07 and 0.05 mg/kg, respectively).

SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 value of 7.7, and is utilized in asthma research [1].

CCR8 antagonist 3 (compound 2), a potent inhibitor of CCR8, exhibits an IC 50 value of 0.062 µM and demonstrates stability in human microsomes [1].

Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody targeting CCR8.